INNATE PHARMA Aktie
1,74EUR | 0,03EUR | 1,64% |
WKN DE: A0LCUJ / ISIN: FR0010331421
Personal
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 237 | 215 | 210 | 179 | 0 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,24 | 0,06 | 0,24 | 0,29 | 0,00 |
Bilanz (in Mio. EUR) - Aktiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 173 | 138 | 140 | 148 | 86 |
Summe Anlagevermögen | 134 | 129 | 68 | 36 | 25 |
Summe Aktiva | 307 | 267 | 208 | 184 | 111 |
Bilanz (in Mio. EUR) - Passiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Summe Fremdkapital | 151 | 160 | 154 | 132 | 102 |
Summe Eigenkapital | 156 | 107 | 54 | 52 | 9 |
Summe Passiva | 307 | 267 | 208 | 184 | 111 |
Adresse
117, Avenue de Luminy, 13009 Marseille | |
Telefon | +33 (4) 30-30-30-30 |
Internet | http://www.innate-pharma.com |
Management
Claire de Saint Blanquat
Secretary, VP-Legal & Corporate Affairs |
Eric Vivier
Chief Scientific Officer & Senior Vice President |
Frederic Lombard
Chief Financial Officer & Senior Vice President |
Gilles Brisson
Member-Supervisory Board |
Guillaume Gimonet
Senior Director-Launch Excellence |
Henry Wheeler
Vice President-Investor Relations & Communications |
Irina Staatz-Granzer
Chairman-Supervisory Board |
Jean-Yves Blay
Independent Member-Supervisory Board |
Jonathan Dickinson
Chairman-Executive Board & CEO |
Nicola Beltraminelli
Chief Development Officer & Vice President |
Odile Belzunce
Vice President-Compliance & Operations |
Odile Laurent
VP-Human Resources & Social Relations |
Olivier Martinez
Member-Supervisory Board |
Pascale Boissel
Independent Member-Supervisory Board |
Sally Bennett
Independent Member-Supervisory Board |
Samuel Dalens
Director |
Sonia Quaratino
Chief Medical Officer & Executive Vice President |
Véronique Chabernaud
Independent Member-Supervisory Board |
Yannis Morel
Chief Operating Officer & Executive Vice President |